期刊文献+

玻璃体腔内注射康柏西普的围手术期规范化护理干预的效果评价 被引量:1

Observation of Peri-operative Nursing Effect of Intravitreal Injection of Conbercept
下载PDF
导出
摘要 目的:观察年龄相关性黄斑变性(AMD)、糖尿病视网膜病变、视网膜静脉阻塞等患者行玻璃体腔注射康柏西普的住院患者,对他们进行围手术期的护理干预,包括围手术期的护理措施及并发症的预防和处理后,是否能够提高患者的就诊质量和治疗效果。方法:随机选取我院在2019年1月至2019年8月期间收治的228例行玻璃体腔内注射康柏西普患者作为研究对象,计算机随机分为两组,每组有114例患者。所有患者注药前的视力在0.01~0.5之间。对围手术期予以规范化护理干预,观察实验组和对照组患者术后视力提高情况以及术后并发症的发生情况。结果:通过1个月后复查得知,实验组患者视力改善率为 85.96%。对照组患者视力改善率为75.44%。 Aim: To observe the inpatients withage-related macular degeneration (AMD), diabetic retinopathy and retinal veinocclusion who received intravitreal injection of conbercept. The perioperativenursing intervention includes perioperative nursing measures and the preventionand treatment of complications, whether it can improve the quality of patients’treatment and treatment effect. Methods: A total of 228 patients admitted toour hospital from January 2019 to August 2019 for intravitreal injection ofconbercept were randomly selected as subjects. They were randomly divided intotwo groups, each with 114 patients. The visual acuity of all patients wasbetween 0.01 and 0.5 before injection. Results:According to the review 1 month later, the visual acuity improvementrate of the experimental group was 85.96%. The visual acuity rate of thecontrol group was 75.44%.The visual acuity improvement rate of the two groupswas significantly different (P
出处 《护理学》 2021年第3期145-149,共5页 Nursing Science
  • 相关文献

参考文献10

二级参考文献127

  • 1李军,张军,朱霆,李利,段云燕,张玉顺.肌部室间隔缺损封堵剖析[J].心脏杂志,2005,17(3):273-274. 被引量:2
  • 2Rudnicka AR, Jarrar Z, Wormald R, et al. Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry: a meta-analysis [J]. Ophthalmology, 2012, 119(3): 571-580.
  • 3American Academy of Ophthalmology Retina Panel. Preferred Practice Pattern? Guidelines: comprehensive adult medical eye evaluation E EB/OL]. San Francisco: American Academy of Ophthalmology, 2010 [ 2010-09-11 ]. http://one. Aao. Org/ CE/ Practice Guidelines/ PPP. Asox? o: 1.
  • 4Takashi U, Yasuo N, Takuhiro Y, et al. Systemic vascular safety of ranibizumah for age-related macular degeneration: systematic review and meta-analysis of randomized trials [J]. Ophthalmology, 2014, 121(11) :2193-2203.
  • 5Emerson MV, Lauer AK. Current and emerging therapies for the treatment of age-related macular degeneration [J]. Clin Ophthalmol, 2008, 2(2) :377-388.
  • 6Li X, Xu G, Wang Y, et al. Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12- month randomized phase 2 study: AURORA study [J]. Ophthalmology, 2014, 121(9) :1740-1747.
  • 7Wang Q, Li T,Wu Z, et al. Novel VEGF decoy receptor fusion protein conbercept targeting multiple VEGF isoforms provide remarkable anti-angiogenesis effect in vivo[J/OL]. PLoS One, 2013, 8(8) : 70544[2013-08-12]. http://dx, plos. org/10. 1371/ journal, pone. 0070544.
  • 8Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration [J]. N Engl J Med, 2006, 355:1419-1431.
  • 9Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR Study [J]. Ophthalmology, 2009, 116(1) :57-65.
  • 10Singer MA, Awh CC, Sadda S, et al. HORIZON: an openlabel extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration [J]. Ophthalmology, 2012, 119(6) :1175-1183.

共引文献130

同被引文献9

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部